Trial Profile
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Gosuranemab (Primary)
- Indications Corticobasal degeneration; Primary progressive aphasia; Tauopathies; Traumatic brain injuries
- Focus Adverse reactions
- Acronyms TauBasket
- 30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
- 20 Dec 2019 Status changed from recruiting to discontinued.
- 12 Sep 2018 New trial record